An ongoing dialogue on HIV/AIDS, infectious diseases,
March 20th, 2009
Hair Today, Gone Tomorrow …
Since providers — especially doctors — are notoriously poor at predicting medication adherence, here’s some good news: In a paper from the Women’s Interagency Health Study, protease inhibitor levels in hair samples were the strongest independent predictor of virologic success — better than self-reported adherence, age, race, baseline viral load and CD4 cell count, and prior experience with protease inhibitors.
That’s not all: Dr. Monica Gandhi (the lead investigator) describes the technique:
“We collect a small sample of hair from the back of their head and by small I mean 10 to 15 strands. So we collect after about a month of therapy a small thatch of hair from the back of your head and then grind it up and measure the anti-retroviral in that hair. And that gives us an idea after you start a new regimen whether you have enough in your system,” she says.
And in case you were wondering (were you?):
“One thing that people ask is can we use pubic hair for these measurements. And we don’t think that those are going to be useful because hair in those areas grow to a certain length and then they stop, which is great for anyone who has this hair. But you really want to measure hair that’s sort of growing continuously and that’s really scalp hair,” she says.
Every so often I’m reminded that HIV medicine isn’t like other fields — and that paragraph says it all!
(Hat tip to R Plank for the reference.)
Categories: HIV, Infectious Diseases, Patient Care
Tags: ART, baseline, CD4, Dr. Monica Gandhi, hair samples, HIV, HIV medicine, monica gandhi, predictor, protease inhibitor, protease inhibitors, R Plank, scalp hair, viral load
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
-
From the Blog — Most Recent Articles
- ID Things to Be Grateful for — 2025 Edition November 24, 2025
- When AI Gets the Medical Advice Wrong — and Right November 18, 2025
- Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin November 13, 2025
- Favorite ID Fellow Consults: Johns Hopkins Edition November 7, 2025
- Two Covid Vaccine Studies — One Actionable, the Other Not So Much October 28, 2025
FROM NEJM — Recent Infectious Disease Articles- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk December 4, 2025Highly pathogenic avian influenza A(H5N1) virus has spread among dairy cattle, with virus detected in milk samples. In this report, virus viability after cold storage or pasteurization is assessed.
- Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 December 4, 2025Results from recently published, peer-reviewed studies support the safety and effectiveness of immunizations against Covid-19, RSV, and influenza.
- Glucocorticoids for Pneumonia in Africa — Old Therapy, New Context December 4, 2025The African continent is home to 1.55 billion people, one fifth of the world’s population, spread over an area larger than the United States, China, and India combined. The disease burden is enormous,1 and health care resources are severely constrained. In one multinational survey, one in eight hospitalized...
- The New U.S. Global Health Strategy — A Reset of America’s Health Cooperation December 4, 2025The U.S. administration recently unveiled its new approach to global health. A retreat from multilateralism, a geopolitical emphasis, and rushed transitions could threaten progress.
- Empyema Necessitans December 4, 2025A 66-year-old man presented with 2 weeks of shortness of breath and cough, 5 days of left flank pain, and 2 days of a rapidly expanding mass on his left side.
- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk December 4, 2025
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

